Exciting news for children with rare liver disease

10 September 2020
lab_biotech_test_big-1

Boston, USA-based Albireo Pharma (Nasdaq: ALBO) has released positive top-line results from the Phase III PEDFIC 1 trial of odevixibat.

Shares in the company rose sharply following the announcement and stood more than 50% higher by the close of trading on Tuesday.

Specializing in orphan pediatric liver diseases, Albireo is working on novel bile acid modulators. The firm was founded in Sweden, and was originally spun out of Anglo-Swedish drug major AstraZeneca (LSE: AZN).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology